内容紹介
A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Paclitaxel and Bevacizumab after Radical Mastectomy
Summary
A 61-year-old postmenopausal woman with breast cancer and carcinomatous pleurisy was successfully treated with bevacizumab and paclitaxel. In December 2008, after receiving preoperative chemotherapy consisting of q3w 4 cycles of EC(E: 90 mg/m2, C: 600 mg/m2)and 12 cycles of weekly paclitaxel(80 mg/m2), the patient underwent modified radical mastectomy with axillary lymph node dissection for right breast cancer. Pathological examination showed residual tumor cells and lymph node metastasis(pT4bN2M0, StageⅢb). In July 2012, 3 and a half years later, she complained of a cough and dyspnea. Chest X-ray and computed tomography scans showed a pleural effusion involving the entire left thoracic cavity, indicating carcinomatous pleurisy. Bevacizumab and paclitaxel therapy was initiated. Soon thereafter, the pleural fluid disappeared, tumor marker levels decreased, and symptoms were ameliorated. After 6 cycles of bevacizumab and paclitaxel therapy, the patient continuously received 3 cycles of weekly paclitaxel(80 mg/m2). Two years and 4 months since the diagnosis, she has remained free of carcinomatous pleurisy recurrence. She is currently receiving hormone therapy on an outpatient basis. Bevacizumab and paclitaxel therapy is potentially effective for the treatment of patients with carcinomatous pleurisy, providing a chance for long-term survival.
要旨
乳癌術後癌性胸膜炎に対してpaclitaxel(PTX)+bevacizumab(BEV)併用療法が著効し,長期生存が得られた症例を経験した。症例は61歳,女性。乳癌手術より3年6か月経過し,癌性胸膜炎の診断となった。胸水穿刺後PTX+BEV併用療法を開始,投与後よりCEAの著明な減少を認め,画像検査では改善が確認された。6サイクル実施後,さらにPTX 3サイクルを単剤で追加し,ホルモン療法へ薬物療法を変更した。併用療法開始後より2年4か月経過した現在,胸水の再貯留は確認されていない。癌性胸膜炎に対してPTX+BEV併用療法が有効であり,長期生存が得られる可能性が示された。
目次
Summary
A 61-year-old postmenopausal woman with breast cancer and carcinomatous pleurisy was successfully treated with bevacizumab and paclitaxel. In December 2008, after receiving preoperative chemotherapy consisting of q3w 4 cycles of EC(E: 90 mg/m2, C: 600 mg/m2)and 12 cycles of weekly paclitaxel(80 mg/m2), the patient underwent modified radical mastectomy with axillary lymph node dissection for right breast cancer. Pathological examination showed residual tumor cells and lymph node metastasis(pT4bN2M0, StageⅢb). In July 2012, 3 and a half years later, she complained of a cough and dyspnea. Chest X-ray and computed tomography scans showed a pleural effusion involving the entire left thoracic cavity, indicating carcinomatous pleurisy. Bevacizumab and paclitaxel therapy was initiated. Soon thereafter, the pleural fluid disappeared, tumor marker levels decreased, and symptoms were ameliorated. After 6 cycles of bevacizumab and paclitaxel therapy, the patient continuously received 3 cycles of weekly paclitaxel(80 mg/m2). Two years and 4 months since the diagnosis, she has remained free of carcinomatous pleurisy recurrence. She is currently receiving hormone therapy on an outpatient basis. Bevacizumab and paclitaxel therapy is potentially effective for the treatment of patients with carcinomatous pleurisy, providing a chance for long-term survival.
要旨
乳癌術後癌性胸膜炎に対してpaclitaxel(PTX)+bevacizumab(BEV)併用療法が著効し,長期生存が得られた症例を経験した。症例は61歳,女性。乳癌手術より3年6か月経過し,癌性胸膜炎の診断となった。胸水穿刺後PTX+BEV併用療法を開始,投与後よりCEAの著明な減少を認め,画像検査では改善が確認された。6サイクル実施後,さらにPTX 3サイクルを単剤で追加し,ホルモン療法へ薬物療法を変更した。併用療法開始後より2年4か月経過した現在,胸水の再貯留は確認されていない。癌性胸膜炎に対してPTX+BEV併用療法が有効であり,長期生存が得られる可能性が示された。